AllCells

How did Discovery’s initiative with a CGT developer significantly reduce the risk of failure and CDMO costs?

Tune into our upcoming LinkedIn Live event on 11/13, where Dr. Yuki Kato Maves will present a real-world case study highlighting how we partnered with a CGT developer to optimize the isolation workflow of GMP cryopreserved peripheral blood mononuclear cells (PBMCs), resulting cost and risk reductions.

Register now:

Overcoming the Challenges of Allogeneic PBMC Isolation in GMP Manufacturing | LinkedIn Manufacturing failures in cell and gene therapy (CGT) carry high costs and risks, jeopardizing the timely production and delivery of safe, effective, and scalable allogeneic therapies. In this LinkedIn Live event, Dr. Yuki Kato Maves will present a real-world case study highlighting how Discovery Li...

Are you planning to attend the 6th TIL Therapies Summit at the Colonnade Hotel in Boston next week? Schedule a meeting with us to learn more about how AllCells RUO and GMP products can help advance the tumor-infiltrating lymphocyte therapy development.

Schedule a Meeting: https://dls.com/event/til-therapies-summit/

Connect with Conor Marino for more information.

We're excited to partner with ScaleReady in the inaugural G-Rex® Grant Program—a $20M initiative aimed at advancing CGT development and manufacturing.

Discovery Life Sciences specializes in leukapheresis and custom prospective collections of high-quality CGT starting materials. Through this partnership, G-Rex® Grant recipients gain access to exclusive offers on AllCells® RUO and GMP products.

Learn more: https://www.scaleready.com/g-rex-grant-program/

Discovery’s AllCells RUO and GMP products, combined with integrated analytical services, have supported many CGT programs in transitioning from early discovery to process development and manufacturing, with an average 98% collection deliverability rate.

Connect with us today to discuss your CGT projects: https://allcells.com/contact-us/

G-Rex Grant Program llustrates how ScaleReady works in a true partnership with your T and NK cell therapy program...

A recent clinical trial has shown promising results, with three autoimmune disease patients responding positively to an allogeneic CD19-directed CAR-T therapy.

Read more: https://www.fiercebiotech.com/biotech/allogeneic-car-t-cells-used-treat-autoimmune-disease-first-time

This is the first clinical proof-of-concept demonstrating the efficacy and safety of an “off the shelf” cell therapy for autoimmune disease, marking a significant milestone for the field!

Learn how Discovery's expertise in donor recruitment and management can propel advancements in allogeneic cell therapy development for cancers, autoimmune diseases, and more: https://allcells.com/services/donor-management-program/

In a first, patients with autoimmune diseases respond to allogeneic CAR-T treatment Three people with autoimmune diseases have responded positively to allogeneic CAR-T therapy, marking a first for the "off-the-shelf" cell therapy tech. | In a first, three patients with autoimmune diseases have responded positively to allogeneic CAR-T therapy. The study, conducted in China and publi...